Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

NCT04145297 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Neoplasms

Interventions

DRUG: Ulixertinib
DRUG: Hydroxychloroquine

Sponsor

University of Utah

Collaborators

[object Object]